FDA Issues Final Guidance on Implanted BCIs
The FDA issued final guidance in 2021 on implanted brain-computer interface (BCI) devices for patients with paralysis or amputation, covering nonclinical testing and clinical study design.
Why it matters
The guidance is the regulatory cornerstone of implanted BCI clinical translation in the United States, the framework within which investigational device exemption (IDE) trial designs from Neuralink, Synchron and other developers operate.